Phase I Study of HRS-1635 in B-cell Malignancies

Summary

The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.

Timeline

Start

2026-06-30

Primary completion

2028-10

Completion

2029-12

Drugs

Indications